Partner Pipeline
partner |
program |
source |
area |
phase 1 |
phase 2 |
phase 3 |
registration |
approved |
|---|---|---|---|---|---|---|---|---|
| Gloria Pharmaceuticals Arcus Biosciences Gilead |
Zimberelimab |
OmniRat | Oncology | |||||
| CStone Pharmaceuticals Pfizer |
Sugemalimab |
OmniRat | Oncology | |||||
| J&J Innovative Medicine | Teclistamab |
OmniRat | Oncology | |||||
| Hanall Biopharma Immunovant Harbour BioMed |
Batoclimab |
OmniRat | Immunology | |||||
| Genmab | Acasunlimab |
OmniRat | Oncology | |||||
| SalubrisBio | SAL003 |
OmniRat | Metabolic | |||||
| Genentech | Tiragolumab |
OmniRat | Oncology | |||||
| AbbVie | ABBV-383 |
OmniFlic | Oncology | |||||
| AstraZeneca | AZD0486 |
OmniFlic | Oncology | |||||
| Merck KGaA | M6223 |
OmniRat | Oncology | |||||
| Teva | TEV-53408 |
OmniRat | Gastrointestinal | |||||
| Hanall Biopharma Immunovant |
IMVT-1402 |
OmniRat | Immunology | |||||
| J&J Innovative Medicine | JNJ-70218902 |
OmniRat | Oncology | |||||
| Aptevo Therapeutics | APVO436 |
OmniMouse | Oncology | |||||
| CTTQ | TQB2223 |
OmniRat | Oncology | |||||
| Symphogen by Servier | S95018 |
OmniRat | Oncology | |||||
| Symphogen by Servier | S95024 |
OmniRat | Oncology | |||||
| Symphogen by Servier | S95029 |
OmniRat | Oncology | |||||
| Zhilkang Hongyi | Undisclosed |
OmniRat | Oncology | |||||
| Curon | CN1 |
OmniRat | Oncology | |||||
| Boehringer Ingelheim | BI 765179 |
OmniChicken | Undisclosed | |||||
| Merck KGaA | M9140 |
OmniRat | Oncology | |||||
| J&J Innovative Medicine | JNJ-79635322 |
OmniRat | Oncology | |||||
| Pfizer | PF-08046049 (SGN-BB228) |
OmniRat | Oncology | |||||
| Gloria Pharmaceuticals | GLS-012 |
OmniRat | Oncology | |||||
| Cessation Therapeutics | CSX1004 |
OmniRat | Drug overdose | |||||
| BioCity | BC3195 |
OmniRat | Oncology | |||||
| Teva | TEV-56278 |
OmniChicken | Oncology | |||||
| Genmab | GEN1057 |
OmniRat | Oncology | |||||
| Merck | M5542 |
OmniRat | Immunology | |||||
| Innolake Biopharm | ILB2101 |
OmniRat | Oncology | |||||
| J&J Innovative Medicine | JNJ-87562761 |
OmniRat | Oncology | |||||
| Genmab | GEN1078 |
OmniRat | Undisclosed | |||||
| Partner | Gloria Pharmaceuticals Arcus Biosciences Gilead |
|---|---|
| Program | Zimberelimab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | CStone Pharmaceuticals Pfizer |
| Program | Sugemalimab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | J&J Innovative Medicine |
| Program | Teclistamab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Approved |
| Partner | Hanall Biopharma Immunovant Harbour BioMed |
| Program | Batoclimab |
| Source | OmniRat |
| Area | Immunology |
| Phase | Registration |
| Partner | Genmab |
| Program | Acasunlimab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 3 |
| Partner | SalubrisBio |
| Program | SAL003 |
| Source | OmniRat |
| Area | Metabolic |
| Phase | Phase 3 |
| Partner | Genentech |
| Program | Tiragolumab |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 3 |
| Partner | AbbVie |
| Program | ABBV-383 |
| Source | OmniFlic |
| Area | Oncology |
| Phase | Phase 3 |
| Partner | AstraZeneca |
| Program | AZD0486 |
| Source | OmniFlic |
| Area | Oncology |
| Phase | Phase 3 |
| Partner | Merck KGaA |
| Program | M6223 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 2 |
| Partner | Teva |
| Program | TEV-53408 |
| Source | OmniRat |
| Area | Gastrointestinal |
| Phase | Phase 2 |
| Partner | Hanall Biopharma Immunovant |
| Program | IMVT-1402 |
| Source | OmniRat |
| Area | Immunology |
| Phase | Phase 2 |
| Partner | J&J Innovative Medicine |
| Program | JNJ-70218902 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Aptevo Therapeutics |
| Program | APVO436 |
| Source | OmniMouse |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | CTTQ |
| Program | TQB2223 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen by Servier |
| Program | S95018 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen by Servier |
| Program | S95024 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Symphogen by Servier |
| Program | S95029 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Zhilkang Hongyi |
| Program | Undisclosed |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Curon |
| Program | CN1 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Boehringer Ingelheim |
| Program | BI 765179 |
| Source | OmniChicken |
| Area | Undisclosed |
| Phase | Phase 1 |
| Partner | Merck KGaA |
| Program | M9140 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | J&J Innovative Medicine |
| Program | JNJ-79635322 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Pfizer |
| Program | PF-08046049 (SGN-BB228) |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Gloria Pharmaceuticals |
| Program | GLS-012 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Cessation Therapeutics |
| Program | CSX1004 |
| Source | OmniRat |
| Area | Drug overdose |
| Phase | Phase 1 |
| Partner | BioCity |
| Program | BC3195 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Teva |
| Program | TEV-56278 |
| Source | OmniChicken |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Genmab |
| Program | GEN1057 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Merck |
| Program | M5542 |
| Source | OmniRat |
| Area | Immunology |
| Phase | Phase 1 |
| Partner | Innolake Biopharm |
| Program | ILB2101 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | J&J Innovative Medicine |
| Program | JNJ-87562761 |
| Source | OmniRat |
| Area | Oncology |
| Phase | Phase 1 |
| Partner | Genmab |
| Program | GEN1078 |
| Source | OmniRat |
| Area | Undisclosed |
| Phase | Phase 1 |
Program placement is based on most advanced status
Italicized programs do not have future or remaining economics to OmniAb